Posted on 2/3/20
Allen Business Advisors Announces Event Schedule for 2020
Allen Business Advisors (AllenBusinessAdvisors.com), a business brokerage firm operating nationally that specializes in selling architectural, engineering, and land surveying businesses as well as healthcare practices, announced . . .
Posted on 2/3/20
New England Bioassay Spins Out From GZA as New, Independent Firm
New England Bioassay Inc. (NEB), a leading provider of ecological and wastewater-toxicity testing, has reached an agreement to spin out from longtime owner GZA GeoEnvironmental Inc.
Posted on 2/3/20
Implanet Reverse Stock Split Takes Effect
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee-surgery implants, today . . .
Posted on 2/3/20
Biotech Bankruptcies Hit Recent High in 2019
Biotech investors might have had an exciting year in 2019 with an impressive amount of new drug approvals. There were 14 notable bankruptcies last year as . . .
Posted on 2/3/20
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Bristol-Myers Squibb (NYSE:BMY) announced on Friday afternoon that it has withdrawn its European application for the company's Opdivo/Yervoy lung cancer drug combo. The company had hoped . . .
Posted on 2/3/20
Where Will Vertex Pharmaceuticals Be in 10 Years?
It's easy to grasp how Vertex Pharmaceuticals (NASDAQ:VRTX) got to where it is today. A decade ago, the biotech's market cap hovered around $8 billion. Vertex's . . .
Posted on 2/7/20
MEDITECH Expanse Awarded Best in KLAS for Acute Care EMR and Category Leader for Community Patient Accounting
WESTWOOD, Mass.--(BUSINESS WIRE)--MEDITECH, a leading Enterprise Health Record (EHR) vendor, is pleased to announce Expanse, its fully interoperable web-based platform, has been recognized in two key . . .
Posted on 1/31/20
Is Biogen Stock a Buy?
Ahead of the opening bell this morning, biotech heavyweight Biogen (NASDAQ:BIIB) posted stronger-than-expected fourth-quarter results. The biotech exceeded Factset's consensus estimates for both its top and . . .
Posted on 1/31/20
Biogen's Earnings Per Share Jumped 19% in Fourth Quarter
Biogen (NASDAQ:BIIB) delivered its fourth-quarter earnings report on Thursday, showing revenue up 4% year-over-year to $3.67 billion. Adjusted income of $1.49 billion was up 6% year . . .
Posted on 1/31/20
DentaQuest Named ‘Best’ in Dental Plan Customer Satisfaction by J.D. Power for Fourth Consecutive Year
BOSTON--(BUSINESS WIRE)--DentaQuest, the nation’s leading purpose-driven oral health organization, ranks highest in customer satisfaction with dental plan insurers, according to the 2019 J.D. Power Dental Plan . . .
Posted on 1/31/20
Catabasis Pharmaceuticals Prices $23M Underwritten Public Offering
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,600,000 shares of . . .
Posted on 1/31/20
Concert Pharmaceuticals Closes Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 5,735,283 shares of its common stock to . . .
Posted on 1/31/20
Medicinal Genomics Expands Global Reach with Distribution Partners in South America and Southeast Asia
Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its partnerships with three . . .
Posted on 1/31/20
Albireo Prices $40M Public Offering of Common Stock
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today . . .
Posted on 1/30/20
Flexion Therapeutics: A Good Foundation For Growth In 2020
SummaryFlexion ended 2019 with $73 million in Zilretta net sales.The stock pulled back after the company issued 2020 revenue guidance that was below the Street consensus . . .
Posted on 1/30/20
Catabasis Pharmaceuticals Proposes Underwritten Public Offering
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed offering . . .
Posted on 1/30/20
Black Diamond Therapeutics Prices IPO
CAMBRIDGE, Mass. and NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ: BDTX), a precision oncology medicine company pioneering the discovery and . . .
Posted on 1/30/20
Massachusetts Nurse of 30 Years Named Medline's First "Works of Heart" Program Honoree
Medline today announced the first honoree of its new "Works of Heart" program that honors healthcare workers across the country for their attention, compassion and dedication.Connie . . .
Posted on 1/29/20
Albireo Announces Proposed Public Offering of Common Stock
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today . . .
Posted on 1/29/20
Biohaven Announces Pricing Of $250 Million Public Offering Of Common Shares
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical?stage biopharmaceutical company with a portfolio of innovative, late?stage product candidates targeting neurological diseases, including rare disorders, today . . .
Posted on 1/29/20
Current Health Collaborates with Mass General Hospital
NEW YORK--(BUSINESS WIRE)--Current Health, which offers the leading FDA-cleared, artificial intelligence (AI)-powered patient management platform, today announced that it will collaborate with Massachusetts General Hospital (MGH) . . .
Posted on 1/29/20
Concert Pharmaceuticals Prices Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 4,752,420 shares of its common stock at a public . . .
Posted on 1/29/20
Biohaven Announces Proposed Public Offering Of Common Shares
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical?stage biopharmaceutical company with a portfolio of innovative, late?stage product candidates targeting neurological diseases, including rare disorders, today . . .
Posted on 1/28/20
Genprex Announces Closing of $8 Million At-The-Market Common Stock Offering
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to . . .
Posted on 1/28/20
ImmunoGen Announces Closing of Public Offering and to Purchase Additional Shares
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of . . .

